Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Increase of Number of Shares and Votes in Hansa Medical AB (publ)

Regulatory information
Lund, Sweden, October 31, 2018 - Hansa Medical AB (NASDAQ Stockholm:HMED), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of October 2018. 

As previously announced on September 6, 2018. Hansa’s board of directors resolved to issue 391,503 class C shares, by virtue of authorization by the general meeting held on May 29, 2018. Furthermore, the Hansa general meeting resolved to adopt a warrant program 2015-2019 on June 2, 2015. As part of the completion of the program, 50,000 ordinary shares have been issued.

All class C shares are owned by the Company. The share issue forms part of the Company’s long-term incentive program, and the purpose of the repurchase is to ensure delivery of shares and to secure possible social charges arising as a result of LTIP 2018.

As of today, the total number of registered and outstanding shares of Hansa amounts to 38,904,889, whereof 38,183,125 are ordinary shares and 721,764 are class C shares. As of today, the number of votes in Hansa amounts to 38,255,301.4, and the registered share capital amounts to SEK 38,904,889.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:00am CET on October 31, 2018.